Ropes & Gray represented HilleVax, Inc. on its exclusive license agreement with Chengdu Kanghua Biological Products Co., Ltd. (Kangh) for rights to Kangh’s hexavalent virus-like particle (VLP) vaccine candidate for norovirus outside of Greater China.
As part of the exclusive license agreement, Kangh will supply the VLP vaccine candidate for use in HilleVax’s near-term clinical trials, including a Phase 1 trial that HilleVax expects to initiate in 2024.
HilleVax will pay Kangh $15 million upfront with the potential for additional payments of up to $255.5 million if certain developmental and sales milestones are met. Kangh is also eligible to receive a single-digit tiered royalty on net sales outside of Greater China. The agreement was announced in a press release on Jan. 8.
Norovirus causes approximately 700 million cases of moderate-to-severe acute gastroenteritis and 200,000 deaths per year globally, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year.
The team was led by IP transactions partner Geoffrey Lin and associate Dan Freshman.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.